Literature DB >> 33729819

Could boron-containing compounds (BCCs) be effective against SARS-CoV-2 as anti-viral agent?

E Cetiner, K Sayin, B Tuzun, H Ataseven.   

Abstract

BACKGROUND: Seven dioxaborole compounds are investigated in this study. Structural and spectral characterizations are done at the M062X/6-31+G(d,p) level in water. Active sites of these compounds are determined by contour plots of frontier molecular orbital and molecular electrostatic potential (MEP) maps. Electrophilic and nucleophilic attack regions are determined. Since SARS-CoV-2 is a worldwide health problem, antiviral properties of studied boron-containing compounds are investigated by molecular docking calculations. In addition to these calculations, MM/PSBA calculations are performed. RESULTS AND
CONCLUSION: It is found that the studied boron compounds can be good drug candidates against the main protease of SARS-CoV-2, while the best of them is 4,6-di-tert-butyl-2-(4-methoxyphenyl)benzo[d][1,3,2] dioxaborole (B2) (Tab. 3, Fig. 8, Ref. 23).

Entities:  

Keywords:  SARS-CoV-2 MD calculations.; boronate ester; dioxaborole; in silico

Mesh:

Substances:

Year:  2021        PMID: 33729819     DOI: 10.4149/BLL_2021_044

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  2 in total

1.  ADME properties, bioactivity and molecular docking studies of 4-amino-chalcone derivatives: new analogues for the treatment of Alzheimer, glaucoma and epileptic diseases.

Authors:  Meliha Burcu Gürdere; Yakup Budak; Umit M Kocyigit; Parham Taslimi; Burak Tüzün; Mustafa Ceylan
Journal:  In Silico Pharmacol       Date:  2021-05-03

2.  Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial.

Authors:  Neda Akbari; Alireza Ostadrahimi; Helda Tutunchi; Samira Pourmoradian; Nazila Farrin; Farzad Najafipour; Hamid Soleimanzadeh; Behnam Kafil; Majid Mobasseri
Journal:  J Trace Elem Med Biol       Date:  2022-02-12       Impact factor: 3.995

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.